Every 8-K that CYTODYN INC (CYDY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CYDY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYDY filings page.
CytoDyn Inc. is holding an investor call and has furnished presentation slides outlining a corporate and clinical update focused on its CCR5-targeting drug candidate, leronlimab, in oncology. The materials highlight the Phase 2 CLOVER trial in third-line metastatic colorectal cancer, where all 91 screened patients tested CCR5-positive and leronlimab has been well tolerated with no Grade 3 or 4 adverse events or serious adverse events attributed to the drug.
Early CLOVER data from City of Hope show 100% of the first 19 patients had circulating tumor DNA declines, with a median 70% reduction by week 2, and 15 of 22 patients with week‑8 RECIST data showed tumor shrinkage or stable disease. Retrospective triple‑negative breast cancer data suggest reductions in circulating tumor cells and PD‑L1 upregulation in many patients, including a small group who received immune checkpoint inhibitors and remain alive after more than five years. The presentation also outlines a clinical roadmap through 2027 and notes a planned $17.5 million financing to support continued leronlimab development and an expanded access program.
CytoDyn Inc. amended two secured convertible promissory notes originally issued in April 2021, each with an initial principal amount of $28.5 million. On March 24, 2026, the company and the noteholders agreed to extend the maturity dates of these notes by 36 months to April 5, 2029 and April 23, 2029, respectively.
As consideration for the extensions, CytoDyn will make combined monthly payments valued at $1,000,000 in shares of common stock through the new maturity dates, with the share value based on the lower of the prior day’s closing price or the average closing price over the previous five trading days. The annual interest rate on each note was reduced to 5%, lowering the cash interest burden while committing to ongoing equity-based payments.
CytoDyn Inc. reported several recent private financing transactions that together raised new cash and issued additional common shares and warrants. Through a placement agent offering begun in January 2026, the company received binding subscriptions for about 81.4 million units at $0.2153 per unit, for roughly $17.5 million in cash; each unit includes one share and a five-year warrant with a $0.26 exercise price. CytoDyn also sold 3,944,773 shares directly to an accredited investor for about $1.0 million, and a separate investor bought 464,468 similar units for $100,000. Under a standby equity purchase agreement with Yorkville, the company issued about 0.8 million shares for roughly $0.2 million. In addition, it exchanged portions of a convertible note into new notes and issued about 5.9 million shares to the noteholder in satisfaction of $1.5 million of principal.
CytoDyn Inc. reported that it has reached an agreement in principle to settle a federal securities class action, Courter et al. v. CytoDyn Inc., pending in the Western District of Washington. The proposed settlement calls for the company to provide $500,000 in cash and 49 million shares of its common stock to the plaintiff class in exchange for dismissal and release of all claims against all defendants.
The agreement remains subject to final documentation, court approval, and other conditions, and the company emphasizes there is no assurance the settlement will be completed on the anticipated terms, or at all. CytoDyn states the agreement does not constitute an admission of fault or liability. If the settlement is not finalized or approved, the company plans to continue defending the case and notes that an adverse outcome could materially affect its financial condition, results of operations, and cash flows.
CytoDyn Inc. reported that stockholders approved an amendment to its certificate of incorporation and the company filed a Certificate of Amendment in Delaware to increase its authorized common stock from 1,750,000,000 to 2,250,000,000 shares. This change expands the number of shares the company is permitted to issue in the future but does not itself represent a new issuance.
At the 2025 annual meeting, stockholders elected all five director nominees to serve until the 2026 annual meeting. They also approved, on an advisory basis, the selection of CBIZ CPAs P.C. as independent registered public accounting firm for the fiscal year ending May 31, 2026, and supported the compensation of named executive officers.
In a separate advisory vote, stockholders chose to hold future advisory votes on executive compensation every one year, reinforcing an annual say-on-pay cadence.
CytoDyn Inc. entered a Standby Equity Purchase Agreement with Yorkville, giving the company the right for 36 months to sell common stock in periodic advances up to an aggregate $30,000,000, subject to conditions. Shares sold in any advance are priced at 98% of the lowest daily VWAP over a three‑day pricing period after an advance notice, within trading volume limits and other customary caps.
Yorkville’s ownership is limited to 4.99% of outstanding voting power at any time. Closing each advance requires an effective SEC registration statement covering the resale of the commitment shares and any advance shares. CytoDyn paid a $25,000 structuring fee and will pay a 1.00% commitment fee in common shares, half within five days and half at six months. Net proceeds from any sales are expected to be used for working capital and general corporate purposes, including repayment of debt.